Tg Therapeutics (TGTX) Other Non-Current Assets (2010 - 2026)
Tg Therapeutics (TGTX) posted quarterly Other Non-Current Assets of $1.4 million for Q1 2026, up 3.84% year-over-year from $1.3 million in Q1 2025, and down 33.86% quarter-over-quarter from $2.0 million in Q4 2025.
Tg Therapeutics (TGTX) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Tg Therapeutics' Other Non-Current Assets history runs 17 years deep, the most recent figure standing at $1.4 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 3.84% year-over-year to $1.4 million; the TTM figure through Mar 2026 stood at $1.4 million (up 3.84% YoY), while the FY2025 annual figure was $2.0 million, up 57.47% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $1.4 million, down from $2.0 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $2.2 million in Q2 2024, with the low at $1.3 million in Q1 2022.
- The 5-year median for Other Non-Current Assets is $1.3 million (2024), against an average of $1.5 million.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Assets jumped 68.49% in 2024, then sank 38.93% in 2025.
- Tg Therapeutics' Other Non-Current Assets stood at $1.3 million in 2022, then advanced by 0.94% to $1.3 million in 2023, then increased by 1.01% to $1.3 million in 2024, then jumped by 57.47% to $2.0 million in 2025, then slumped by 33.86% to $1.4 million in 2026.
- Business Quant data shows TGTX's Other Non-Current Assets at $1.4 million in Q1 2026, $2.0 million in Q4 2025, and $2.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Tg Therapeutics | 7.46 Bn | 6.78 Bn | 199.14 Mn | 2.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.21 Mn |
| Mar 31, 2026 | 1.35 Mn |
| Dec 31, 2025 | 2.04 Mn |
| Sep 30, 2025 | 2.05 Mn |
| Jun 30, 2025 | 1.32 Mn |
| Mar 31, 2025 | 1.30 Mn |
| Dec 31, 2024 | 1.30 Mn |
| Sep 30, 2024 | 2.11 Mn |
| Jun 30, 2024 | 2.16 Mn |
| Mar 31, 2024 | 1.29 Mn |
| Dec 31, 2023 | 1.29 Mn |
| Sep 30, 2023 | 1.28 Mn |
| Jun 30, 2023 | 1.28 Mn |
| Mar 31, 2023 | 1.28 Mn |
| Dec 31, 2022 | 1.27 Mn |
| Sep 30, 2022 | 1.27 Mn |
| Jun 30, 2022 | 1.27 Mn |
| Mar 31, 2022 | 1.27 Mn |
| Dec 31, 2021 | 1.26 Mn |
| Sep 30, 2021 | 1.26 Mn |